Natera Inc. Common Stock vs Zscaler Inc — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Zscaler Inc trades at $218.07 (market cap $36.81B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Zscaler Inc for 41 Days on average.
| NTRA | ZS | |
|---|---|---|
Market Cap | $57.03B | $36.81B |
Volume | 1,131,157 | 2,661,492 |
Sector | Health | Technology |
52-Week High | $425.64 | $336.27 |
52-Week Low | $179.42 | $118.05 |
Typical Hold Time | 0 Days | 41 Days |
Enterprise Value | $56.18B | $35.20B |
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Zscaler (ZS) trades at $220.79, down 2.21% on the day, amid mixed signals. The stock shows strong technical momentum with bullish moving averages, but RSI suggests potential overbought conditions. Fundamentally, revenue growth is robust, rising from $1.1B in 2022 to $2.67B in 2025, though the company remains unprofitable with a net income margin of -1.88%. Recent news includes executive changes and an upcoming Investor Day on October 6, 2026.
The outlook is cautiously optimistic. Analyst consensus is strongly bullish with a $222.83 price target, but risks include persistent losses, competitive pressures, and insider selling. Upside hinges on AI-driven bookings growth and execution stability post-CRO transition. Investors should weigh high valuation multiples against the company's growth trajectory and market position in cybersecurity.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →